Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volociximab + DTIC in Metastatic Melanoma
NCT00099970Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Dec 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volociximab in melanoma, sponsored by PDL BioPharma. Primary endpoint: Objective Response Rate. Started Dec 2004; status: completed.
02
Drugs
volociximab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00099970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099970.